Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus

American Journal of Cardiology

Volumn 111, Issue 8, 2013, Pages 1123-1130

  Navarese, Eliano Pio ^a   Buffon, Antonino ^b   Andreotti, Felicita ^b   Kozinski, Marek ^a   Welton, Nicky ^c   Fabiszak, Tomasz ^a   Caputo, Salvatore ^b   Grzesk, Grzegorz ^a   Kubica, Aldona ^a   Swiatkiewicz, Iwona ^a   Sukiennik, Adam ^a   Kelm, Malte ^d   De Servi, Stefano ^e   Kubica, Jacek ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e Civic Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; HUMAN; META ANALYSIS; PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT;

DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84875850647     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.12.037     Document Type: Article

References (29)

1. N. Thongtang, M. Ai, S. Otokozawa, T.V. Himbergen, B.F. Asztalos, K. Nakajima, E. Stein, P.H. Jones, and E.J. Schaefer Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation Am J Cardiol 107 2011 387 392
2. N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, A.J. de Craen, S.R. Seshasai, J.J. McMurray, D.J. Freeman, J.W. Jukema, P.W. Macfarlane, C.J. Packard, D.J. Stott, R.G. Westendorp, J. Shepherd, B.R. Davis, S.L. Pressel, R. Marchioli, R.M. Marfisi, A.P. Maggioni, L. Tavazzi, G. Tognoni, J. Kjekshus, T.R. Pedersen, T.J. Cook, A.M. Gotto, M.B. Clearfield, J.R. Downs, H. Nakamura, Y. Ohashi, K. Mizuno, K.K. Ray, and I. Ford Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
3. D. Preiss, S.R. Seshasai, P. Welsh, S.A. Murphy, J.E. Ho, D.D. Waters, D.A. DeMicco, P. Barter, C.P. Cannon, M.S. Sabatine, E. Braunwald, J.J. Kastelein, J.A. de Lemos, M.A. Blazing, T.R. Pedersen, M.J. Tikkanen, N. Sattar, and K.K. Ray Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
4. United States Food and Drug Administration. FDA expands advice on statin risks. Available at: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330. htm. Accessed November 24, 2012.
5. A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gøtzsche, J.P. Ioannidis, M. Clarke, P.J. Devereaux, J. Kleijnen, and D. Moher The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 339 2009 b2700
6. G. Lu, and A. Ades Combination of direct and indirect evidence in mixed treatment comparisons Stat Med 23 2004 3105 3124
7. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 2: a generalised linear modelling framework for pair-wise and network meta-analysis 2011. Available at: http://www.nicedsu.org.uk. Accessed November 24, 2012.
8. P.S. Sever, B. Dahlöf, N.R. Poulter, H. Wedel, G. Beevers, M. Caulfield, R. Collins, S.E. Kjeldsen, A. Kristinsson, G.T. McInnes, J. Mehlsen, M. Nieminen, E. O'Brien, J. Ostergren ASCOT investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158
9. R. Collins, J. Armitage, S. Parish, P. Sleight, R. Peto Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2003 2005 2016
10. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., J.J. Kastelein, W. Koenig, P. Libby, A.J. Lorenzatti, J.G. MacFadyen, B.G. Nordestgaard, J. Shepherd, J.T. Willerson, R.J. Glynn JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
11. D.J. Freeman, J. Norrie, N. Sattar, R.D. Neely, S.M. Cobbe, I. Ford, C. Isles, A.R. Lorimer, P.W. Macfarlane, J.H. McKillop, C.J. Packard, J. Shepherd, and A. Gaw Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study Circulation 103 2001 357 362
12. A. Keech, D. Colquhoun, J. Best, A. Kirby, R.J. Simes, D. Hunt, W. Hague, E. Beller, M. Arulchelvam, J. Baker, A. Tonkin LIPID Study Group Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial Diabetes Care 26 2003 2713 2721
13. J. Kjekshus, E. Apetrei, V. Barrios, M. Böhm, J.G. Cleland, J.H. Cornel, P. Dunselman, C. Fonseca, A. Goudev, P. Grande, L. Gullestad, A. Hjalmarson, J. Hradec, A. Jánosi, G. Kamenský, M. Komajda, J. Korewicki, T. Kuusi, F. Mach, V. Mareev, J.J. McMurray, N. Ranjith, M. Schaufelberger, J. Vanhaecke, D.J. van Veldhuisen, F. Waagstein, H. Wedel, J. Wikstrand CORONA Group Rosuvastatin in older patients with systolic heart failure N Engl J Med 357 2007 2248 2261
14. J. Shepherd, G.J. Blauw, M.B. Murphy, E.L. Bollen, B.M. Buckley, S.M. Cobbe, I. Ford, A. Gaw, M. Hyland, J.W. Jukema, A.M. Kamper, P.W. Macfarlane, A.E. Meinders, J. Norrie, C.J. Packard, I.J. Perry, D.J. Stott, B.J. Sweeney, C. Twomey, R.G. Westendorp PROSPER Study Group Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630
15. H. Nakamura, K. Arakawa, H. Itakura, A. Kitabatake, Y. Goto, T. Toyota, N. Nakaya, S. Nishimoto, M. Muranaka, A. Yamamoto, K. Mizuno, Y. Ohashi MEGA Study Group Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial Lancet 368 2006 1155 1163
16. J.R. Downs, M. Clearfield, S. Weis, E. Whitney, D.R. Shapiro, P.A. Beere, A. Langendorfer, E.A. Stein, W. Kruyer, and A.M. Gotto Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
17. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
18. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) JAMA 288 2002 2998 3007
19. L. Tavazzi, A.P. Maggioni, R. Marchioli, S. Barlera, M.G. Franzosi, R. Latini, D. Lucci, G.L. Nicolosi, M. Porcu, G. Tognoni GISSI-HF Investigators Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial Lancet 372 2008 1231 1239
20. GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio Della Sopravvivenza Nell'Infarto Miocardico) Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? Ital Heart J 1 2000 810 820
21. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, S.V. Joyal, K.A. Hill, M.A. Pfeffer, A.M. Skene Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
22. J.C. LaRosa, S.M. Grundy, D.D. Waters, C. Shear, P. Barter, J.C. Fruchart, A.M. Gotto, H. Greten, J.J. Kastelein, J. Shepherd, N.K. Wenger Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
23. T.R. Pedersen, O. Faergeman, J.J. Kastelein, A.G. Olsson, M.J. Tikkanen, I. Holme, M.L. Larsen, F.S. Bendiksen, C. Lindahl, M. Szarek, J. Tsai Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445
24. P. Amarenco, J. Bogousslavsky, A. Callahan III, L.B. Goldstein, M. Hennerici, A.E. Rudolph, H. Sillesen, L. Simunovic, M. Szarek, K.M. Welch, J.A. Zivin Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 2006 549 559
25. K.K. Koh, S. Lim, I. Sakuma, and M.J. Quon Caveats to aggressive lowering of lipids by specific statins Int J Cardiol 154 2012 97 101
26. D. Preiss, and N. Sattar Statins and the risk of new-onset diabetes: a review of recent evidence Curr Opin Lipidol 22 2011 460 466
27. K.K. Koh, M.J. Quon, I. Sakuma, S.H. Han, H. Choi, K. Lee, and E.K. Shin Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients Int J Cardiol 2011 [Epub ahead of print]
28. Zaharan NL, Williams D, Bennett K. Statins and Risk of Treated Incident Diabetes in a Primary Care Population. Br J Clin Pharmacol. In press.
29. B. Mihaylova, J. Emberson, L. Blackwell, A. Keech, J. Simes, E.H. Barnes, M. Voysey, A. Gray, R. Collins, C. Baigent Cholesterol Treatment Trialists' (CTT) Collaborators The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590